Clinical Trials Logo

Clinical Trial Summary

Usage of a guideline-compliant SOP in each chest pain unit (CPU) is instrumental in establishing the diagnosis of a pulmonary embolism without time delay. With the integration of this SOP as a "clinical decision tool" (CDT) into the electronic database of the CPU, the standardized application of the pulmonary embolism SOP in the clinical routine of the CPU will be tested using a retro- and prospective approach.


Clinical Trial Description

Summary:

The increasing number of patients in the emergency departments in recent years extends the time until diagnosis and treatment initiation and thus represents a serious problem in patient care and for the treating physician. This also includes patients with acute pulmonary embolism (PE), which is one of the most common differential diagnoses of patients presenting with unclear dyspnea, chest pain or other symptoms in the emergency department. Due to the potentially serious clinical outcome with a high overall mortality rate of > 10%, rapid diagnosis and initiation of therapy is essential.

The current guidelines of the European Society of Cardiology for the diagnosis and treatment of acute PE recommend a stringent diagnostic algorithm that includes clinical parameters as well as risk scores for estimating the pretest probability. Depending of their results the further diagnostic pathway by D-Dimer testing and / or CT angiography is chosen.

The aim of the present study is to examine the standardized application of guideline recommendations of the European Society of Cardiology (ESC). The diagnostic procedures were defined for the CPU of the University Hospital Heidelberg in a standard operating procedure (SOP). In the planned retrospective study, the implementation of this SOP will be examined on the basis of the QEST criteria (quality, efficacy, safety and transparency). Data for the "actual condition" are collected retrospectively for 6 months prior to August 2019, thereafter for another 6 months after implementation of the quality assurance measure.

Introduction and fundamental principles:

Acute pulmonary embolism (PE), with a prevalence of 1.22-1.83 persons per 100,000 population, is the third most common cardiovascular disease and represents a serious disease with a 30-day mortality from potential right ventricular dysfunction with cardiogenic shock estimated at 16%. Approximately 65% of all deaths occur within the first hours after admission. The prognosis of pulmonary embolism is highly variable and depends in particular on the severity of the hemodynamic impairment as well as on concomitant morbidities.

Due to multiple and sometimes non-specific symptoms, the diagnosis of PE poses a clinical challenge and requires much clinical experience in order not to overlook the diagnosis. Clinical scores (Well's Score, Geneva Score, modified Geneva Score) and the overall clinical impression (gestalt) are used to estimate the pretest probability. The current guidelines of the European Society of Cardiology on the diagnosis and management of acute pulmonary embolism recommend a stringent diagnostic algorithm which includes clinical parameters and the above-mentioned risk scores for the assessment of the pretest probability and on the basis of them further diagnostic steps by D-dimer measurement and / or CT angiography. With a low pretest probability, a pulmonary embolism can be excluded with a probability of nearly 100%. On the other hand, if there is a high pretest probability, no D-dimer determination should be made, as even a negative result will not be able to exclude the diagnosis with certainty. The procedure for a mean pretest probability depends on the D-dimer test used. Determination of D-dimers should only be undertaken if an analytically sensitive D-dimer test is present, which is ideally authorized for the purpose of diagnostic exclusion. The central laboratory of the University Hospital of Heidelberg uses the Siemens Liason D-Dimer test, which is considered one of the most sensitive tests. From the diagnostic procedure, a sequential pathway is recommended in which first the pre-test probability and then - depending on the estimate - the D-dimer determination follows. If pulmonary embolism cannot be ruled out, further diagnostic imaging should be provided. CT angiography with a multi-slice device (> 16-slices) is considered the diagnostic gold standard.

However, the guideline-compliant algorithm for the diagnosis of PE has so far only been investigated in a few prospective, randomized studies.

The aim of the present study is to test the standardized use of the pulmonary embolism SOP in the clinical routine of the CPU compared to the "actual state". Currently, the attending physician has unrestricted access to the determination of the D-dimer concentration, and the diagnostic process continues to be carried out at clinical discretion. These two approaches are to be tested and compared with regard to the QEST criteria (quality, efficacy, safety and transparency). ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04049370
Study type Observational
Source Heidelberg University
Contact Vitali Koch, Dr.
Phone 0049 6221-56 8676
Email Vitali.Koch@med.uni-heidelberg.de
Status Not yet recruiting
Phase
Start date August 1, 2019
Completion date January 31, 2020

See also
  Status Clinical Trial Phase
Recruiting NCT05050617 - Point-of-Care Ultrasound in Predicting Adverse Outcomes in Emergency Department Patients With Acute Pulmonary Embolism
Terminated NCT04558125 - Low-Dose Tenecteplase in Covid-19 Diagnosed With Pulmonary Embolism Phase 4
Not yet recruiting NCT06017271 - Predictive Value of Epicardial Adipose Tissue for Pulmonary Embolism and Death in Patients With Lung Cancer
Completed NCT03915925 - Short-term Clinical Deterioration After Acute Pulmonary Embolism
Completed NCT02502396 - Rivaroxaban Utilization for Treatment and Prevention of Thromboembolism in Cancer Patients: Experience at a Comprehensive Cancer Center
Recruiting NCT05171075 - A Study Comparing Abelacimab to Dalteparin in the Treatment of Gastrointestinal/Genitourinary Cancer and Associated VTE Phase 3
Completed NCT04454554 - Prevalence of Pulmonary Embolism in Patients With Dyspnea on Exertion (PEDIS)
Completed NCT03173066 - Ferumoxytol as a Contrast Agent for Pulmonary Magnetic Resonance Angiography Phase 1
Terminated NCT03002467 - Impact Analysis of Prognostic Stratification for Pulmonary Embolism N/A
Completed NCT02611115 - Optimizing Protocols for the Individual Patient in CT Pulmonary Angiography. N/A
Completed NCT02334007 - Extended Low-Molecular Weight Heparin VTE Prophylaxis in Thoracic Surgery Phase 1/Phase 2
Completed NCT01975090 - The SENTRY Clinical Study N/A
Not yet recruiting NCT01357941 - Need for Antepartum Thromboprophylaxis in Pregnant Women With One Prior Episode of Venous Thromboembolism (VTE) N/A
Completed NCT01326507 - Prognostic Value of Heart-type Fatty Acid-Binding Protein (h-FABP) in Acute Pulmonary Embolism N/A
Completed NCT00720915 - D-dimer to Select Patients With First Unprovoked Venous Thromboembolism Who Can Have Anticoagulants Stopped at 3 Months N/A
Completed NCT00773448 - Screening for Occult Malignancy in Patients With Idiopathic Venous Thromboembolism N/A
Completed NCT00771303 - Ruling Out Pulmonary Embolism During Pregnancy:a Multicenter Outcome Study
Completed NCT02476526 - Safety of Low Dose IV Contrast CT Scanning in Chronic Kidney Disease Phase 4
Completed NCT00780767 - Angiojet Rheolytic Thrombectomy in Case of Massive Pulmonary Embolism Phase 2
Completed NCT00244725 - Odiparcil For The Prevention Of Venous Thromboembolism Phase 2